• HOME
  • ABOUT
  • NEWS
  • CONTACT US
  • HOME
  • ABOUT
  • NEWS
  • CONTACT US
  • CinRx News
  • May 8, 2023
CinRx Portfolio Company CinDome Pharma Presents Encouraging Data on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference

CinDome Pharma, a CinRx portfolio company, presented a poster at the 2023 Digestive Disease Week (DDW) Conference.

More

About Author

At Labstica, we believe in the power of collaboration, innovation, and continuous growth – both for our clients and ourselves.

  • LinkedIn
  • Instagram
  • Twitter
  • Facebook

Recent Post

CinRx Appoints Rez Halse, PhD, as President to Lead Its Portfolio of Clinical-Stage Development Companies and Accelerate Growth
February 2, 2026
CinDome Pharma Announces Enrollment Completion in the envision3D Phase 2 Clinical Trial of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis
September 9, 2025
CinDome Pharma Announces First Patient Dosed in Clinical Trial of Deudomperidone (CIN-102)
June 6, 2025

Tags

2023 Digestive Disease Week Conference Acquisition AstraZeneca Biotechnology Business Finance CIN-102 CIN-102 (deudomperidone) CinCor Pharma CinDome CinDome Pharma CinRx Pharma Deudomperidone Deuterated Domperidone Diabetic Gastroparesis envision Financing First Patient Dosed Funding Announcement Gastroparesis Healthcare Finance News Investment Pharmaceutical Funding Pharmaceutical Industry Phase 2 Clinical Trial Phase 2 Trial Poster presented Present a Poster Series B Extension vTv Therapeutics Inc.

844-531-1834 | info@cinrx.com

© 2025 CINRx Pharma. All Rights Reserved.

Site Pages

  • HOME
  • ABOUT
  • NEWS
  • CONTACT US
  • HOME
  • ABOUT
  • NEWS
  • CONTACT US

CINRx in The News

CinRx Appoints Rez Halse, PhD, as President to Lead Its Portfolio of Clinical-Stage Development Companies and Accelerate Growth

February 10, 2026
Read More

CinDome Pharma Announces Enrollment Completion in the envision3D Phase 2 Clinical Trial of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis

September 3, 2025
Read More

FOLLOW US

Linkedin-in

INVESTOR INQUIRIES

CinRx INQUIRIES